Houlihan Lokey Advises Novo Holdings

Houlihan Lokey is pleased to announce that Novo Holdings A/S (Novo Holdings), a leading global life sciences investor, has agreed to acquire Medical Knowledge Group (MKG), an analytics-driven drug commercialization platform servicing the biopharmaceutical industry, from Court Square Capital and Aisling Capital. The transaction closed on February 1, 2022.

Novo Holdings is a private limited liability company wholly owned by the Novo Nordisk Foundation. It is the holding company of the Novo Group, comprising Novo Nordisk A/S and Novozymes A/S, and is responsible for managing the Novo Nordisk Foundation’s assets.

Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets.

Medical Knowledge Group is an analytics-driven drug commercialization platform servicing the biopharmaceutical industry. Through its various operating companies, MKG delivers healthcare-provider-targeted solutions designed to maximize the clinical and commercial potential of the brands they support. MKG partners with some of the world’s largest biopharmaceutical companies as well as niche biotechnology firms.

MKG was founded in 2004 by Chief Executive Officer Leon Behar. Over the past 17 years, MKG has grown to more than 500 employees across four offices located in New York, New Jersey, and Georgia.

Houlihan Lokey served as the exclusive financial advisor to Novo Holdings. This deal highlights Houlihan Lokey’s leading experience in the pharma services space and represents the firm’s 13th transaction in this sector since 2019.